This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations

Friday, May 12, 2017

Submitted by


Source Name: Circulation Research


David D. Waters, Priscilla Y. Hsue

A short and readable commentary on monoclonal antibodies and dyslipidaemias, particularly on FOURIER,  SPIRE and ODYSSEY trials

Add comment

Log in or register to post comments